Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2007

View Archived Issues

Neuren to acquire Hamilton

TargeGen begins phase II trial of TG-100801 eye drops for AMD

Positive results for Novogen's antiinflammatory FAIMs in preclinical studies

Lexicon completes phase I trials of LX-6171 for cognitive disorders

AVEO's oral antiangiogenic agent heads for phase II evaluation in RCC

Phase II study data on vicriviroc presented

Sanofi-aventis and Chugai marketing collaboration in Japan terminated

New treatment options for cardiovascular diseases discussed in recent patent literature

New compounds for the treatment of neurological disorders claimed in recent patents

New antiarthritic drugs claimed in recent patent literature

Positive interim results from AlphaVax's phase I influenza vaccine trial

Astion's ASF-1096 recommended orphan drug status by EMEA

Kyowa Hakko receives MHLW approval for antiepileptic agent KW-6485

Banyu receives MHLW approval for Singulair fine granule 4 mg for infant bronchial asthma

Incyte reports second quarter 2007 results

FDA accepts Fentanyl MDTS IND from Acrux; phase I trial to begin

Poniard begins phase II trial of intravenous picoplatin with Taxotere and prednisone

Javelin begins phase III trial of intranasal ketamine for breakthrough cancer pain

Phase II trial of trastuzumab-DM1 begins; ImmunoGen receives milestone payment

AlphaVax proceeds with the development of a smallpox vaccine

Inactivated whole-virion SARS vaccine immunogenic and protective in hamster model

Erythropoietin modulates emotional responses in humans

Accentia submits pre-IND application for Revimmune

YM begins enrollment of phase II trial of nimotuzumab for colorectal cancer

Positive interim results for OncoGenex and Isis' phase II OGX-011 trial

Antigenics applies for Oncophage approval for kidney cancer in Russia

Second FDA approvable letter issued for Trexima

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...